Skip to main content
Erschienen in: Supportive Care in Cancer 1/2018

08.08.2017 | Original Article

Making an informed decision of Korean cancer patients: the discrepancy between a patient’s recall of information and the information needed for acquisition of radiotherapy informed consent

verfasst von: Hye Ran Lee, Chiyeon Lim, Hyong Geun Yun, Seung Hee Kang, Do Yeun Kim

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

To give informed consent, a patient needs to sufficiently understand the information provided by a physician to decide among treatment options. Although shared decision-making is becoming an important aspect of patient-centered care, little is known about decision-making by cancer patients in Korea.

Objectives

This study assessed Korean cancer patients’ understanding of treatment goals and the need to obtain further information after a physician obtained informed consent for radiotherapy.

Methods

In this prospective study, doctors and patients completed questionnaires independently after informed consent for radiotherapy had been obtained. The questionnaires for the doctors and patients were comprised of matched items regarding treatment aims and the need for further information.

Results

The study enrolled 103 cancer patients scheduled for radiotherapy. The proportion of respondents who stated that the intent of treatment was to bring about a cure was 80.6% among the patients (83 of 103 patients) and 53.4% (55 of 103 patients) among the doctors (p = 0.000). The proportion of respondents who believed that the aim was prolongation of life was 16.5 and 1.9%, respectively (p = 0.000). Regarding the need for further information, 42.7% (44/103) of the patients did not want further information because they had faith in the physicians’ medical expertise.

Conclusion

Many Korean cancer patients misunderstand the aims of treatment and half of participants do not want further information. Physicians should address whether specific interventions can solve these barriers so that Korean cancer patients can make truly autonomous treatment decisions.
Literatur
1.
Zurück zum Zitat Schachter M, Fins JJ (2008) Oncologist. Informed consent revisited: a doctrine in the service of cancer care. Oncologist 13(10):1109–1113CrossRef Schachter M, Fins JJ (2008) Oncologist. Informed consent revisited: a doctrine in the service of cancer care. Oncologist 13(10):1109–1113CrossRef
2.
Zurück zum Zitat Coulter A (2003) Patient information and shared decision-making in cancer care. Br J Cancer 89(Suppl 1):S15–S16CrossRef Coulter A (2003) Patient information and shared decision-making in cancer care. Br J Cancer 89(Suppl 1):S15–S16CrossRef
3.
Zurück zum Zitat Thorne S, Oliffe JL, Stajduhar KI (2013) Communicating shared decision-making: cancer patient perspectives. Patient Edu Couns 90(3):291–296CrossRef Thorne S, Oliffe JL, Stajduhar KI (2013) Communicating shared decision-making: cancer patient perspectives. Patient Edu Couns 90(3):291–296CrossRef
4.
Zurück zum Zitat Yun YH, Lee CG, Kim SY, Lee SW, Heo DS, Kim JS, Lee KS, Hong YS, Lee JS, You CH (2004) The attitudes of cancer patients and their families toward the disclosure of terminal illness. J Clin Oncol (22, 2):307–314CrossRef Yun YH, Lee CG, Kim SY, Lee SW, Heo DS, Kim JS, Lee KS, Hong YS, Lee JS, You CH (2004) The attitudes of cancer patients and their families toward the disclosure of terminal illness. J Clin Oncol (22, 2):307–314CrossRef
5.
Zurück zum Zitat Jie B, Qiu Y, Feng ZZ, Zhu SN (2016) Impact of disclosure of diagnosis and patient autonomy on quality of life and illness perceptions in Chinese patients with liver cancer. Psychooncology 25(8):927–932CrossRef Jie B, Qiu Y, Feng ZZ, Zhu SN (2016) Impact of disclosure of diagnosis and patient autonomy on quality of life and illness perceptions in Chinese patients with liver cancer. Psychooncology 25(8):927–932CrossRef
7.
Zurück zum Zitat Quirt CF, Mackillop WJ, Ginsburg AD, Sheldon L, Brundage M, Dixon P, Ginsburg L (1997) Do doctors know when their patients don't? A survey of doctor-patient communication in lung cancer. Lung Cancer 18(1):1–20CrossRef Quirt CF, Mackillop WJ, Ginsburg AD, Sheldon L, Brundage M, Dixon P, Ginsburg L (1997) Do doctors know when their patients don't? A survey of doctor-patient communication in lung cancer. Lung Cancer 18(1):1–20CrossRef
8.
Zurück zum Zitat Gabrijel S, Grize L, Helfenstein E, Brutsche M, Grossman P, Tamm M, Kiss A (2008) Receiving the diagnosis of lung cancer: patient recall of information and satisfaction with physician communication. J Clin Oncol 26(2):297–302CrossRef Gabrijel S, Grize L, Helfenstein E, Brutsche M, Grossman P, Tamm M, Kiss A (2008) Receiving the diagnosis of lung cancer: patient recall of information and satisfaction with physician communication. J Clin Oncol 26(2):297–302CrossRef
9.
Zurück zum Zitat Leydon GM, Boulton M, Moynihan C, Jones A, Mossman J, Boudioni M, McPherson K (2000) Cancer patients' information needs and information seeking behavior: in depth interview study. BMJ 320(7239):909–913CrossRef Leydon GM, Boulton M, Moynihan C, Jones A, Mossman J, Boudioni M, McPherson K (2000) Cancer patients' information needs and information seeking behavior: in depth interview study. BMJ 320(7239):909–913CrossRef
10.
Zurück zum Zitat Samson P, Waters EA, Meyers B, Politi MC (2016) Shared decision making and effective risk communication in the high-risk patient with operable stage I non-small cell lung cancer. Ann Thorac Surg 101(6):2049–2052CrossRef Samson P, Waters EA, Meyers B, Politi MC (2016) Shared decision making and effective risk communication in the high-risk patient with operable stage I non-small cell lung cancer. Ann Thorac Surg 101(6):2049–2052CrossRef
11.
Zurück zum Zitat Shuman AG, Larkin K, Thomas D, Palmer FL, Fins JJ, Baxi SS, Lee N, Shah JP, Fagerlin A, Patel SG (2017) Patient reflections on decision making for laryngeal cancer treatment. Otolaryngol Heand Neck Surg 156(2):299–304CrossRef Shuman AG, Larkin K, Thomas D, Palmer FL, Fins JJ, Baxi SS, Lee N, Shah JP, Fagerlin A, Patel SG (2017) Patient reflections on decision making for laryngeal cancer treatment. Otolaryngol Heand Neck Surg 156(2):299–304CrossRef
12.
Zurück zum Zitat Pujol JL, Mérel JP, Roth C (2016) How preconceptions about lung cancer treatment interact with medical discourse for patients who accept chemotherapy? Psycho Oncology. doi:10.1002/pon.4231 CrossRef Pujol JL, Mérel JP, Roth C (2016) How preconceptions about lung cancer treatment interact with medical discourse for patients who accept chemotherapy? Psycho Oncology. doi:10.​1002/​pon.​4231 CrossRef
13.
Zurück zum Zitat Tariman JD, Doorenbos A, Schepp KG, Singhal S, Berry DL (2014) Information needs priorities in patients diagnosed with cancer: a systematic review. J Adv Pract Oncol 2014(5):115–122PubMed Tariman JD, Doorenbos A, Schepp KG, Singhal S, Berry DL (2014) Information needs priorities in patients diagnosed with cancer: a systematic review. J Adv Pract Oncol 2014(5):115–122PubMed
14.
Zurück zum Zitat Kim DY, Lee KE, Nam EM, Lee HR, Lee KW, Kim JH, Lee JS, Lee SN (2007) Do-not-resuscitate orders for terminal patients with cancer in teaching hospitals of Korea. J Palliat Med 10(5):1153–1158CrossRef Kim DY, Lee KE, Nam EM, Lee HR, Lee KW, Kim JH, Lee JS, Lee SN (2007) Do-not-resuscitate orders for terminal patients with cancer in teaching hospitals of Korea. J Palliat Med 10(5):1153–1158CrossRef
Metadaten
Titel
Making an informed decision of Korean cancer patients: the discrepancy between a patient’s recall of information and the information needed for acquisition of radiotherapy informed consent
verfasst von
Hye Ran Lee
Chiyeon Lim
Hyong Geun Yun
Seung Hee Kang
Do Yeun Kim
Publikationsdatum
08.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3848-8

Weitere Artikel der Ausgabe 1/2018

Supportive Care in Cancer 1/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.